SCHEMBL3001230

SCHEMBL3001230

CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccc(N(C)C)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.55
ALDH1A1 P00352 8/20 0.55
HSD17B10 Q99714 6/20 0.55
GAA P10253 5/20 0.55
LMNA P02545 3/20 0.55
HPGD P15428 2/20 0.55
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
TSHR P16473 4/20 0.51
CYP2C9 P11712 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C19 P33261 2/20 0.51
HIF1A Q16665 2/20 0.51
ADORA3 P0DMS8 2/20 0.51
MAPT P10636 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
TP53 P04637 1/20 0.51
CYP2D6 P10635 1/20 0.51
NFKB1 P19838 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006534 0.86 KDM4E (0.66) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL3001176 0.80 DHFR (0.66) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL7257040 0.77 KDM4E (0.60) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL3037183 0.76 KDM4E (0.64) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL11814442 0.75 KDM4E (0.63) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL10746434 0.74 DHFR (0.58) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL11688373 0.73 DHFR (0.61) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL11819754 0.73 KDM4E (0.66) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL7106117 0.73 KDM4E (0.56) KDM4EALDH1A1HSD17B10GAALMNA
SCHEMBL11450739 0.73 CYP2C9 (0.79) KDM4EALDH1A1HSD17B10GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US claimed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US claimed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US claimed
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R KDM4E 1088/4885ALDH1A1 274/4885HSD17B10 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.